Ramucirumab + Gemcitabine + Docetaxel
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Synovial Sarcoma
Conditions
Synovial Sarcoma
Trial Timeline
Mar 4, 2020 → Feb 23, 2023
NCT ID
NCT04145700About Ramucirumab + Gemcitabine + Docetaxel
Ramucirumab + Gemcitabine + Docetaxel is a phase 1/2 stage product being developed by Eli Lilly for Synovial Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04145700. Target conditions include Synovial Sarcoma.
What happened to similar drugs?
1 of 4 similar drugs in Synovial Sarcoma were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04145700 | Phase 1/2 | Terminated |
Competing Products
8 competing products in Synovial Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 2 | 39 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 44 |
| Pexidartinib | Daiichi Sankyo | Approved | 43 |
| LV305 + G305 | Merck | Phase 3 | 32 |
| TBI-1301 + Cyclophosphamide | Takara Bio | Phase 1/2 | 32 |
| TBI-1301 + Cyclophosphamide + Fludarabine | Takara Bio | Phase 3 | 47 |
| FHD-609 | Foghorn Therapeutics | Phase 1 | 11 |
| CFT8634 | C4 Therapeutics | Phase 1 | 11 |